FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2023年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 775
相关论文
共 50 条
  • [1] FDA approves first GPRC5D x CD3-targeted bispecific for multiple myeloma
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (10) : 775 - 775
  • [2] Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma
    Jeong, Jihong
    Park, Junhyeon
    Mo, Geun Young
    Shin, Jinwoo
    Cho, Yunje
    JOURNAL OF MOLECULAR BIOLOGY, 2024, 436 (20)
  • [3] Targeting GPRC5D in multiple myeloma
    Elemian, Shatha
    Al Hadidi, Samer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 229 - 238
  • [4] Targeting GPRC5D for multiple myeloma therapy
    Zhou, Dian
    Wang, Ying
    Chen, Chong
    Li, Zhenyu
    Xu, Kailin
    Zhao, Kai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [5] Doubling down on GPRC5D in multiple myeloma
    Neri, Paola
    BLOOD, 2025, 145 (02) : 146 - 148
  • [6] FDA approves first-in-class bispecific for multiple myeloma
    不详
    NATURE BIOTECHNOLOGY, 2023, 41 (09) : 1181 - 1181
  • [7] FDA approves first-in-class bispecific for multiple myeloma
    Nature Biotechnology, 2023, 41 : 1180 - 1180
  • [8] GPRC5D as a novel immunotherapeutic target in multiple myeloma
    Karthik Nath
    Bruno A. Costa
    Sham Mailankody
    Nature Reviews Clinical Oncology, 2023, 20 : 281 - 282
  • [9] GPRC5D as a novel immunotherapeutic target in multiple myeloma
    Nath, Karthik
    Costa, Bruno A.
    Mailankody, Sham
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (05) : 281 - 282
  • [10] Bispecific and trispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
    Roth, Hayley
    Rogers, Daniel
    Sanchez, Ileine
    Tyrell, Breanna
    Barnes, Trevor
    Snyder, Ami
    Nowgu, Nenna
    Doolan, Kyle
    Doranz, Benjamin J.
    Chambers, Ross
    Rucker, Joseph B.
    CANCER RESEARCH, 2024, 84 (06)
12345